Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-R in Untreated Burkitt Lymphoma
NCT01092182Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2010
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), plasmablastic lymphoma (PBL), sponsored by National Cancer Institute. Started Mar 2010; status: completed.
02
Drugs
etoposideprednisonevincristinecyclophosphamidedoxorubicin
03
Conditions
Burkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT01092182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01092182.